PremiumThe FlyEdwards Lifesciences price target raised to $75 from $71 at Canaccord Hold Rating on Edwards Lifesciences: Balancing Positive Trends with TAVR Uncertainties Texas Instruments, Mondelez downgraded: Wall Street’s top analyst calls PremiumThe FlyClosing Bell Movers: Robert Half down 15% after earnings miss Edwards Lifesciences reaffirms FY25 adjusted EPS $2.40-$2.50, consensus $2.45 Edwards Lifesciences reports Q1 EPS 61c, consensus 60c PremiumRatingsBalanced Outlook on Edwards Lifesciences Amid TMTT Growth and TAVR Market Challenges Edwards Lifesciences receives CE Mark for Sapien M3 Edwards Lifesciences price target lowered to $75 from $78 at Truist 
